Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
NCT ID NCT01063647
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing whether a chemotherapy drug called treosulfan, given in different doses along with fludarabine, can safely prepare patients with advanced blood cancers for a stem cell transplant. The study focuses on patients who are not eligible for the standard, more intense conditioning regimens due to increased toxicity risk. The goal is to see if this approach is feasible and tolerable, and whether it can help keep the cancer in remission after the transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Treosulfan (a chemotherapy drug) combined with fludarabine, used as a conditioning regimen before stem cell transplantation
- What this could lead to
- If successful, this could provide a safer conditioning option for patients with blood cancers who cannot tolerate standard high-dose chemotherapy or radiation, potentially improving transplant outcomes.
- What could go wrong
- This is an early-phase trial with a small number of patients, so results may not be conclusive. The treatment carries risks of serious side effects, including transplant-related mortality and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
5th Medical Clinic, Clinic North
Nuremberg, 90340, Germany
-
Charité University Hospital Berlin
Berlin, 12203, Germany
-
Helsinki University Central Hospital
Helsinki, FIN-00290, Finland
-
Karolinska University Hospital & Karolinska Institute
Stockholm, 141 86, Sweden
-
Silesian Medical University
Katowice, 40-029, Poland
-
University Hospital Hamburg Eppendorf
Hamburg, 20246, Germany
-
University Hospital Rostock
Rostock, 18057, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a modified enzyme starve Hard-to-Treat blood cancers?